Samsung Biologics (207940) stock
Samsung Biologics technical analysis
Oscillators
Summary
Moving averages
| Oscillators | Value | Signal |
|---|---|---|
| RSI (14) | 43.06 | Neutral |
| Stochastic %K (14, 3, 3) | 11.89 | Neutral |
| CCI (20) | -127.63 | Buy |
| ADX (14) | 15.53 | Neutral |
| Awesome Oscillator | 3,826.47 | Neutral |
| Momentum (10) | -161,000 | Sell |
| MACD (12, 26) | -2,545.93 | Sell |
| Stoch RSI (3, 3, 14, 14) | 2.262 | Neutral |
| Williams %R (14) | -86.77 | Neutral |
| Bull Bear Power | -118,065.91 | Neutral |
| Ultimate Oscillator (7, 14, 28) | 49.6 | Neutral |
| Moving averages | Value | Signal |
|---|---|---|
| EMA (10) | ₩1,405,237.08 | Sell |
| SMA (10) | ₩1,420,100.00 | Sell |
| EMA (20) | ₩1,412,726.68 | Sell |
| SMA (20) | ₩1,432,850.00 | Sell |
| EMA (30) | ₩1,411,331.97 | Sell |
| SMA (30) | ₩1,395,100.00 | Sell |
| EMA (50) | ₩1,413,135.36 | Sell |
| SMA (50) | ₩1,389,712.23 | Sell |
| EMA (100) | ₩1,431,215.98 | Sell |
| SMA (100) | ₩1,432,066.12 | Sell |
| EMA (200) | ₩1,476,710.63 | Sell |
| SMA (200) | ₩1,483,923.06 | Sell |
| Ichimoku Base Line (9, 26, 52, 26) | ₩1,397,000.00 | Sell |
| VWMA (20) | ₩1,444,869.76 | Sell |
| Hull MA (9) | ₩1,355,522.22 | Sell |
Support & resistance levels
Resistance
- R5₩1,877,331.37+38.55%Strong
- R4₩1,830,000.00+35.06%Weak
- R3₩1,778,000.00+31.22%Weak
- R2₩1,626,122.84+20.01%Strong
- R1₩1,440,527.51+6.31%Strong
Support
- S1₩1,302,069.11-3.91%Moderate
- S2₩1,243,182.93-8.25%Moderate
- S3₩1,150,000.00-15.13%Weak
Levels are detected automatically from swing highs and lows on the daily chart and clustered by volatility (ATR). Strength reflects the number of times price reacted at each level.
| Pivot points (daily) | S3 | S2 | S1 | P | R1 | R2 | R3 |
|---|---|---|---|---|---|---|---|
| Classic | ₩1,306,666.67 | ₩1,322,333.33 | ₩1,348,666.67 | ₩1,364,333.33 | ₩1,390,666.67 | ₩1,406,333.33 | ₩1,432,666.67 |
| Fibonacci | ₩1,322,333.33 | ₩1,338,377.33 | ₩1,348,289.33 | ₩1,364,333.33 | ₩1,380,377.33 | ₩1,390,289.33 | ₩1,406,333.33 |
| Camarilla | ₩1,363,450.00 | ₩1,367,300.00 | ₩1,371,150.00 | ₩1,364,333.33 | ₩1,378,850.00 | ₩1,382,700.00 | ₩1,386,550.00 |
| Woodie | ₩1,312,000.00 | ₩1,325,000.00 | ₩1,354,000.00 | ₩1,367,000.00 | ₩1,396,000.00 | ₩1,409,000.00 | ₩1,438,000.00 |
| DeMark | — | — | ₩1,354,000.00 | ₩1,367,000.00 | ₩1,396,000.00 | — | — |
Samsung Biologics price forecast
| Horizon | Bear case (95%) | Low (68%) | Trend target | High (68%) | Bull case (95%) |
|---|---|---|---|---|---|
| 5 trading days | ₩1,179,323.75 | ₩1,262,778.59 | ₩1,352,139.12 -0.2% | ₩1,447,823.25 | ₩1,550,278.47 |
| 21 trading days | ₩1,014,785.32 | ₩1,167,425.33 | ₩1,343,024.84 -0.9% | ₩1,545,037.35 | ₩1,777,435.77 |
| 63 trading days | ₩812,018.40 | ₩1,035,069.97 | ₩1,319,391.09 -2.6% | ₩1,681,811.77 | ₩2,143,785.00 |
The technical bias for Samsung Biologics is bearish (overall rating: Strong Sell).
Bullish scenario: a sustained break above ₩1,440,527.51 would open the way toward ₩1,626,122.84.
Bearish scenario: a daily close below ₩1,302,069.11 could extend the decline toward ₩1,243,182.93.
Statistical ranges are based on historical volatility and trend, not a guarantee of future prices. Not financial advice.
About Samsung Biologics
Samsung Biologics (207940) shares are trading at ₩1,355,000.00, down -1.45% today. The company belongs to the Health Care sector and has a market capitalization of ₩65.73T.
The stock’s 52-week range is ₩1,150,000.00 – ₩1,987,000.00, with a price-to-earnings ratio of —. It has moved -5.24% over the past week and +11.16% over the past month.
On the daily chart the overall technical rating for Samsung Biologics is Strong Sell, with the 14-day RSI at 43.1. The nearest support is at ₩1,302,069.11 and the nearest resistance at ₩1,440,527.51.
Related markets
AllStock market news
-
3 Top AI Stocks With At Least 14% ROEYahoo Finance58 min. ago
-
Vietnam Export Stocks Worth Watching As Trade Rules TightenYahoo Finance59 min. ago
-
3 Industrial Stocks Trading Above $500 a Share: Which One Splits First?The Motley Fool1 hr. ago
-
US MARKETS CALL: A Bull-Market Correction Or A Tech-Wreck Bear Market? Also: Our New S&P 500 Targets.Yardeni QuickTakes1 hr. ago
-
Nasdaq Targets 2027 Equity Token Launch as AI and FinTech Growth AccelerateYahoo Finance2 hr. ago
-
3 Canadian Growth Stocks To Own In November 2026Yahoo Finance2 hr. ago
-
3 US Utility Stocks Built For Higher Interest RatesYahoo Finance2 hr. ago
-
3 Stocks I'm Ready to Buy if the Market CrashesYahoo Finance2 hr. ago